1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
5 Porters Five Force Analysis
5.1 Threat of New Entrants
5.2 Bargaining Power of Buyers/Consumers
5.3 Bargaining Power of Suppliers
5.4 Threat of Substitute Products
5.5 Intensity of Competitive Rivalry
6 MARKET SEGMENTATION
6.1 By Product Type
6.1.1 Oral Drugs (Value and Volume, 2012-2024)
6.1.1.1 Biguanides
6.1.1.1.1 Metformin
6.1.1.2 Alpha-Glucosidase Inhibitors
6.1.1.2.1 Alpha-Glucosidase Inhibitors
6.1.1.3 Dopamine D2 receptor agonist
6.1.1.3.1 Bromocriptin
6.1.1.4 SGLT-2 inhibitors
6.1.1.4.1 Invokana (Canagliflozin)
6.1.1.4.2 Jardiance (Empagliflozin)
6.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
6.1.1.4.4 Suglat (Ipragliflozin)
6.1.1.5 DPP-4 inhibitors
6.1.1.5.1 Onglyza (Saxagliptin)
6.1.1.5.2 Tradjenta (Linagliptin)
6.1.1.5.3 Vipidia/Nesina(Alogliptin)
6.1.1.5.4 Galvus (Vildagliptin)
6.1.1.6 Sulfonylureas
6.1.1.6.1 Sulfonylureas
6.1.1.7 Meglitinides
6.1.1.7.1 Meglitinides
6.1.2 Insulins (Value and Volume, 2012-2024)
6.1.2.1 Basal or Long Acting Insulins
6.1.2.1.1 Lantus (Insulin Glargine)
6.1.2.1.2 Levemir (Insulin Detemir)
6.1.2.1.3 Toujeo (Insulin Glargine)
6.1.2.1.4 Tresiba (Insulin Degludec)
6.1.2.1.5 Basaglar (Insulin Glargine)
6.1.2.2 Bolus or Fast Acting Insulins
6.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
6.1.2.2.2 Humalog (Insulin Lispro)
6.1.2.2.3 Apidra (Insulin Glulisine)
6.1.2.3 Traditional Human Insulins
6.1.2.3.1 Novolin/Actrapid/Insulatard
6.1.2.3.2 Humulin
6.1.2.3.3 Insuman
6.1.2.4 Biosimilar Insulins
6.1.2.4.1 Insulin Glargine Biosimilars
6.1.2.4.2 Human Insulin Biosimilars
6.1.3 Combination drugs (Value and Volume, 2012-2024)
6.1.3.1 Insulin combinations
6.1.3.1.1 NovoMix (Biphasic Insulin Aspart)
6.1.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
6.1.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
6.1.3.2 Oral Combinations
6.1.3.2.1 Janumet (Sitagliptin and Metformin)
6.1.4 Non-Insulin Injectable drugs (Value and Volu, 2012-2024)
6.1.4.1 GLP-1 receptor agonists
6.1.4.1.1 Victoza (Liraglutide)
6.1.4.1.2 Byetta (Exenatide)
6.1.4.1.3 Bydureon (Exenatide)
6.1.4.1.4 Trulicity (Dulaglutide)
6.1.4.1.5 Lyxumia (Lixisenatide)
6.1.4.2 Amylin Analogue
6.1.4.2.1 Symlin (Pramlintide)
6.2 Geography
6.2.1 North America (Value and Volume, 2012-2024)
6.2.1.1 United States
6.2.1.1.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
6.2.1.1.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)
6.2.1.2 Canada
6.2.1.2.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
6.2.1.2.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)
6.2.1.3 Rest of North America
6.2.1.3.1 By Product (Oral drugs, Insulins, Combination drugs and Non-Insulin injectables)
6.2.1.3.2 By Company (NovoNordisk, Sanofi Aventis, Eli Lilly, Bristol Myers Squibb and others)
7 MARKET INDICATORS
7.1 Type-1 Diabetes population (2012-2024)
7.2 Type-2 Diabetes population (2012-2024)
8 COMPETITIVE LANDSCAPE
8.1 COMPANY PROFILES
8.1.1 Novo Nordisk A/S
8.1.2 Sanofi Aventis
8.1.3 Eli Lilly
8.1.4 Astra Zeneca
8.1.5 Bristol Myers Squibb
8.1.6 Boehringer Ingelheim
8.1.7 Mylan
8.1.8 Pfizer
8.1.9 Janssen Pharmaceuticals
8.1.10 Merck
8.1.11 Astellas
8.1.12 Teva
8.1.13 Takeda
8.1.14 Bayer
8.1.15 Sun Pharma
8.2 COMPANY SHARE ANALYSIS
8.2.1 Novo Nordisk A/S
8.2.2 Sanofi Aventis
8.2.3 Eli Lilly
8.2.4 Astra Zeneca
8.2.5 Janssen Pharmaceuticals
8.2.6 Merck
8.2.7 Astellas
9 MARKET OPPORTUNITIES AND FUTURE TRENDS